Key result
This review discusses the mechanism of action and clinical trials of angiotensin II receptor blockers (ARBs) as a viable alternative to ACE inhibitors in treating cardiovascular disease.
Why the study?
Do angiotensin II receptor blockers (ARBs) reduce the risk of cardiovascular disease as an alternative to ACE inhibitors?
Do angiotensin II receptor blockers (ARBs) reduce the risk of cardiovascular disease as an alternative to ACE inhibitors?
This review summarizes the mechanism of action and clinical trial evidence supporting ARBs as a viable alternative to ACE inhibitors for reducing cardiovascular risk.
New approaches to the definition and treatment of hypertension have increased emphasis on reducing overall cardiovascular risk and on targeting the underlying mechanisms of cardiovascular disease. During the past several decades, renin-angiotensin-aldosterone system (RAAS) activation has emerged as an important factor in the pathophysiology of endothelial dysfunction and cardiovascular disease (CVD). Angiotensin-converting enzyme inhibitors (ACEIs) have well-established efficacy for treating CVD, but their use may be limited by intolerable side effects, such as cough and angioedema. Angiotensin II receptor blockers (ARBs), a different class of RAAS inhibitors, are considered a viable alternative to ACEIs. Clinical trials have further elucidated the role of ARBs in CVD. This article reviews the mechanism of action of ARBs and selected clinical trials of ARBs in CVD.
No takes yet. Share an insight, caveat, or question.
Abramov et al. (2012) conducted a review in Cardiovascular disease. Angiotensin II receptor blockers (ARBs) vs. Angiotensin-converting enzyme inhibitors (ACEIs) was evaluated. This review discusses the mechanism of action and clinical trials of angiotensin II receptor blockers (ARBs) as a viable alternative to ACE inhibitors in treating cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: